Search

All-encompassing meeting on ALL highly rated by participants

Almost 200 delegates from over 30 countries benefitted from stimulating and excellent discussions about Acute Lymphoblastic Leukemia (ALL) at the EHA-SWG Scientific Meeting on New Molecular Insights and Innovative Management Approaches for Acute Lymphoblastic Leukemia on April 12-14, 2018 in…

Read more

EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy

The EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy brought together basic science, as well as translational and clinical research on November 23-25, 2017 in Amsterdam, The Netherlands.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

Killer antibodies against AML

Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more